Spain Pulmonary Arterial Hypertension Market Size & Outlook
Spain pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Spain pulmonary arterial hypertension market highlights
- The Spain pulmonary arterial hypertension market generated a revenue of USD 231.1 million in 2023 and is expected to reach USD 333.2 million by 2030.
- The Spain market is expected to grow at a CAGR of 5.4% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 231.1 million |
| Market revenue in 2030 | USD 333.2 million |
| Growth rate | 5.4% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Spain accounted for 3.1% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 133.7 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 46.95% in 2023. Horizon Databook has segmented the Spain pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The market for PAH in this region is anticipated to witness lucrative growth over the forecast period. Spain is taking immense strategic planning in order to curb PAH. For instance, every year on May 5 World Pulmonary Hypertension (PH) day is being celebrated as a remembrance of the first child’s death from PH. This initiative is officially endorsed by 10 rare and affiliated disease organizations, 22 patient associations, and 8 scientific societies.
The Spanish Undiagnosed Rare Diseases Program was initiated by the Institute of Rare Diseases Research (IIER) in response to challenging scenarios in covering the needs of patients suffering from rare diseases. Around 3 million individuals in Spain are affected by rare diseases.
In March 2020, the Spanish Council of Ministers agreed on a new economic administration for orphan medical products. The new rules were proposed to boost investment in the R&D as well as subsequent marketing of orphan medicinal products, guaranteeing their supply. This is expected to help improve results for people suffering from rare diseases.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Spain Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
